Thank you for Subscribing to Life Science Review Weekly Brief
TCR² Therapeutics selects Rosemary Harrison as Chief Business and Strategy Officer.
FREMONT, CA: “We are pleased to welcome Dr. Rosemary Harrison as our first Chief Business and Strategy Officer at TCR² as she has proven throughout her career an ability to work closely with multiple commercial functions to identify and execute clear strategic priorities," states Garry Menzel, Ph.D., President and Chief Executive Officer of TCR² Therapeutics. "We look forward to her immediate operational impact as 2022 is a year full of milestones in which our lead program gavo-cel will enter a Phase 2 clinical trial, TC-510 will enter a Phase 1 clinical trial and several other programs; provide opportunities for strategic dialogue.” TCR² Therapeutics Inc., a clinical-stage cell therapy company developing novel T cell therapies for patients with solid tumors, has appointed Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer. In this role, she will support various activities, including commercial strategy, operational planning, corporate partnerships, and long-term growth opportunities.
Dr. Harrison brings over two decades of global experience in strategic planning, portfolio management, and business development to TCR². Before joining the company, she served as Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics, where she was instrumental in the company's November 2021 acquisition by Pfizer for $2.22 billion. Dr. Harrison has held positions in strategy and research at RA Capital Management and as Head of Rare Diseases at Imbria Pharmaceuticals. She formerly worked as the Head of Portfolio Management and Strategy Planning at the Novartis Institutes for Biomedical Research and as a consultant at Bain & Company. She advised on corporate strategic and operational initiatives. Dr. Harrison graduated from The University of Queensland with a Bachelor of Biotechnology in Drug Design and Development and a Ph.D. in Biotechnology.
“TCR2s first-in-class T cell platform is highly differentiated by leveraging the full TCR complex, independent of HLA and has already demonstrated encouraging clinical data in treatment-refractory solid tumors,” states Dr. Harrison. “I am thrilled to be joining TCR2 during such an important period and look forward to working with the outstanding team to focus priorities and support a clear execution plan.”